Cobertura de los medios
7
Cobertura de los medios
Nombre Sona's 'THT' Cancer Therapy to be Assessed for Efficacy and Ability to Act as a Catalyst to Generate Immune Responses in Research Study Nombre/canal del medio de comunicación Street Insider País/Territorio United States Fecha 9/11/23 Personas Carman Anthony Giacomantonio Nombre 'THT' Cancer Therapy to be Assessed for Efficacy and Ability to Act as a Catalyst to Generate Immune Responses in Research Study Nombre/canal del medio de comunicación Market News Publishing País/Territorio United States Fecha 9/11/23 Personas Carman Anthony Giacomantonio Nombre Sona's 'THT' Cancer Therapy to be Assessed for Efficacy and Ability to Act as a Catalyst to Generate Immune Responses in Research Study Nombre/canal del medio de comunicación InvestorsObserver País/Territorio United States Fecha 9/11/23 Personas Carman Anthony Giacomantonio Nombre Sona's 'THT' Cancer Therapy to be Assessed for Efficacy and Ability to Act as a Catalyst to Generate Immune Responses in Research Study Nombre/canal del medio de comunicación Yahoo! Finance País/Territorio United States Fecha 9/11/23 Personas Carman Anthony Giacomantonio Nombre Sona's 'THT' Cancer Therapy to be Assessed for Efficacy and Ability to Act as a Catalyst to Generate Immune Responses in Research Study Nombre/canal del medio de comunicación Chase País/Territorio United States Fecha 9/11/23 Personas Carman Anthony Giacomantonio Nombre Sona’s ‘THT’ Cancer Therapy to be Assessed for Efficacy and Ability to Act as a Catalyst to Generate Immune Responses in Research Study Nombre/canal del medio de comunicación Health Technology Net País/Territorio United States Fecha 9/11/23 Personas Carman Anthony Giacomantonio Nombre Sona Nanotech Inc.: Sona's 'THT' Cancer Therapy to be Assessed for Efficacy and Ability to Act as a Catalyst to Generate Immune Responses in Research Study Nombre/canal del medio de comunicación FinanzNachrichten.de País/Territorio Germany Fecha 9/11/23 Personas Carman Anthony Giacomantonio